On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma

Noninvasive fibrosis indices can help stratify the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving nucleos(t)ide analogue (NA) therapy. We investigated the predictive performance of on-treatment changes in FIB-4 (△FIB-4) and 1-year FIB-4 values (FIB-4 12M)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hung-Wei, Lai, Hsueh-Chou, Hu, Tsung-Hui, Su, Wen-Pang, Lu, Sheng-Nan, Lin, Chia-Hsin, Hung, Chao-Hung, Chuang, Po-Heng, Wang, Jing-Houng, Lee, Mei-Hsuan, Chen, Chien-Hung, Peng, Cheng-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281667/
https://www.ncbi.nlm.nih.gov/pubmed/32392752
http://dx.doi.org/10.3390/cancers12051177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281667/
https://www.ncbi.nlm.nih.gov/pubmed/32392752
http://dx.doi.org/10.3390/cancers12051177

Ejemplares similares